Symbols / PGEN $4.19 +6.35% Precigen, Inc.

Healthcare • Biotechnology • United States • NMS
PGEN Chart
About

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1/1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis. Further, it provides UltraPorator, a proprietary electroporation device. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 1.48B
Enterprise Value 1.39B Income -429.64M Sales 9.68M
Book/sh 0.06 Cash/sh 0.28 Dividend Yield —
Payout 0.00% Employees 160 IPO —
P/E — Forward P/E -19.05 PEG —
P/S 153.14 P/B 71.02 P/C —
EV/EBITDA -13.49 EV/Sales 144.04 Quick Ratio 2.74
Current Ratio 3.09 Debt/Eq 470.04 LT Debt/Eq —
EPS (ttm) -1.37 EPS next Y -0.22 EPS Growth —
Revenue Growth 283.60% Earnings 2026-05-14 ROA -44.30%
ROE -5.72% ROIC — Gross Margin 0.00%
Oper. Margin -4.75% Profit Margin 0.00% Shs Outstand 353.93M
Shs Float 164.11M Short Float 17.38% Short Ratio 8.31
Short Interest — 52W High 5.47 52W Low 1.11
Beta 1.12 Avg Volume 4.81M Volume 3.64M
Target Price $9.50 Recom Buy Prev Close $3.94
Price $4.19 Change 6.35%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$9.50
Mean price target
2. Current target
$4.19
Latest analyst target
3. DCF / Fair value
$-2.71
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.19
Low
$9.00
High
$10.00
Mean
$9.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-26 main Citizens Market Outperform → Market Outperform $9
2026-03-26 main HC Wainwright & Co. Buy → Buy $10
2025-11-14 main HC Wainwright & Co. Buy → Buy $9
2025-08-19 main JMP Securities Market Outperform → Market Outperform $8
2025-08-19 reit HC Wainwright & Co. Buy → Buy $9
2025-08-15 up JP Morgan Underweight → Neutral —
2025-08-15 main HC Wainwright & Co. Buy → Buy $9
2025-08-13 reit HC Wainwright & Co. Buy → Buy $6
2025-06-12 reit JMP Securities Market Outperform → Market Outperform $6
2025-05-15 reit Cantor Fitzgerald Overweight → Overweight —
2025-03-20 reit Citizens Capital Markets Market Outperform → Market Outperform $6
2025-03-20 reit HC Wainwright & Co. Buy → Buy $6
2025-01-23 reit HC Wainwright & Co. Buy → Buy $6
2025-01-22 reit HC Wainwright & Co. Buy → Buy $6
2025-01-14 reit JMP Securities Market Outperform → Market Outperform $5
2024-11-15 reit HC Wainwright & Co. Buy → Buy $4
2024-08-15 main JMP Securities Market Outperform → Market Outperform $7
2024-08-15 main HC Wainwright & Co. Buy → Buy $4
2024-06-04 reit JMP Securities Market Outperform → Market Outperform $14
2024-06-03 main Stifel Buy → Buy $10
News
RSS: Latest PGEN news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-30 KIRK RANDAL JOE Director and Beneficial Owner of more than 10% of a Class of Security — 4,772,781 $3.30 $15,750,177
2026-03-18 SABZEVARI HELEN Chief Executive Officer — 321,100 — —
2026-03-18 THOMASIAN HARRY JR. Chief Financial Officer — 40,293 — —
2026-03-18 SHAH RUTUL R. Chief Operating Officer — 44,495 — —
2026-03-18 TENNANT PHIL Officer — 42,110 — —
2026-03-18 LEHR DONALD P Officer — 40,443 — —
2026-03-13 GUPTA VINITA D Director — 71,839 — —
2026-03-13 KIRK RANDAL JOE Director and Beneficial Owner of more than 10% of a Class of Security — 143,678 — —
2026-03-13 AGEE NANCY HOWELL Director — 71,839 — —
2026-03-13 TURLEY JAMES S Director — 71,839 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
9.68
+146.73%
3.92
-36.95%
6.22
-76.87%
26.91
Operating Revenue
9.68
+146.73%
3.92
-36.95%
6.22
-76.65%
26.66
Cost Of Revenue
4.82
+13.03%
4.27
-30.27%
6.12
-3.47%
6.34
Reconciled Cost Of Revenue
4.82
+13.03%
4.27
-30.27%
6.12
-3.47%
6.34
Gross Profit
4.86
+1521.35%
-0.34
-422.64%
0.11
-99.48%
20.57
Operating Expense
111.46
+18.12%
94.36
+5.99%
89.03
-6.46%
95.18
Research And Development
41.33
-22.12%
53.07
+9.17%
48.61
+3.06%
47.17
Selling General And Administration
70.13
+69.83%
41.29
+2.17%
40.41
-15.81%
48.01
Total Expenses
116.28
+17.90%
98.63
+3.66%
95.15
-6.27%
101.52
Operating Income
-106.60
-12.56%
-94.70
-6.50%
-88.92
-19.19%
-74.61
Total Operating Income As Reported
-110.51
+18.16%
-135.03
-35.36%
-99.76
-31.74%
-75.73
EBITDA
-243.57
-97.23%
-123.50
-38.41%
-89.23
-42.93%
-62.43
Normalized EBITDA
-100.14
-20.40%
-83.17
-6.10%
-78.39
-27.87%
-61.31
Reconciled Depreciation
3.20
-29.32%
4.53
-32.12%
6.67
-38.06%
10.77
EBIT
-246.77
-92.76%
-128.02
-33.50%
-95.89
-31.02%
-73.19
Total Unusual Items
-143.43
-255.69%
-40.32
-272.16%
-10.84
-867.41%
-1.12
Total Unusual Items Excluding Goodwill
-143.43
-255.69%
-40.32
-272.16%
-10.84
-867.41%
-1.12
Special Income Charges
-3.91
+90.31%
-40.32
-272.16%
-10.84
-867.41%
-1.12
Impairment Of Capital Assets
3.91
-90.31%
40.32
+272.16%
10.84
+867.41%
1.12
Restructuring And Mergern Acquisition
—
—
—
—
Write Off
—
—
—
—
Net Income
-250.64
-98.55%
-126.23
-31.63%
-95.90
-438.68%
28.32
Pretax Income
-250.64
-95.77%
-128.03
-32.86%
-96.36
-20.50%
-79.97
Net Non Operating Interest Income Expense
-0.65
-146.18%
1.41
-49.01%
2.77
+141.70%
-6.64
Interest Expense Non Operating
3.87
+64350.00%
0.01
-98.72%
0.47
-93.09%
6.77
Net Interest Income
-0.65
-146.18%
1.41
-49.01%
2.77
+141.70%
-6.64
Interest Expense
3.87
+64350.00%
0.01
-98.72%
0.47
-93.09%
6.77
Interest Income Non Operating
3.21
+126.73%
1.42
-56.19%
3.24
+2333.83%
0.13
Interest Income
3.21
+126.73%
1.42
-56.19%
3.24
+2333.83%
0.13
Other Income Expense
-143.39
-312.80%
-34.73
-240.27%
-10.21
-896.88%
1.28
Other Non Operating Income Expenses
0.04
-99.23%
5.59
+791.39%
0.63
-59.26%
1.54
Gain On Sale Of Security
-139.52
—
—
—
Tax Provision
0.00
+100.17%
-1.79
-291.48%
-0.46
-142.33%
-0.19
Tax Rate For Calcs
0.00
-100.00%
0.00
+180.00%
0.00
+111.51%
0.00
Tax Effect Of Unusual Items
0.00
+100.00%
-0.56
-942.06%
-0.05
-1946.56%
-0.00
Net Income Including Noncontrolling Interests
-250.64
-98.55%
-126.23
-31.63%
-95.90
-438.68%
28.32
Net Income From Continuing Operation Net Minority Interest
-250.64
-98.55%
-126.23
-31.63%
-95.90
-20.22%
-79.78
Net Income From Continuing And Discontinued Operation
-250.64
-98.55%
-126.23
-31.63%
-95.90
-438.68%
28.32
Net Income Continuous Operations
-250.64
-98.55%
-126.23
-31.63%
-95.90
-20.22%
-79.78
Net Income Discontinuous Operations
—
0.00
0.00
-100.00%
108.09
Minority Interests
—
—
—
—
Normalized Income
-107.21
-23.98%
-86.48
-1.59%
-85.12
-8.22%
-78.66
Net Income Common Stockholders
-429.64
-240.35%
-126.23
-31.63%
-95.90
-438.68%
28.32
Diluted EPS
-1.37
-191.49%
-0.47
-20.51%
-0.39
-378.57%
0.14
Basic EPS
-1.37
-191.49%
-0.47
-20.51%
-0.39
-378.57%
0.14
Basic Average Shares
312.98
+16.90%
267.73
+9.48%
244.54
+22.05%
200.36
Diluted Average Shares
312.98
+16.90%
267.73
+9.48%
244.54
+22.05%
200.36
Diluted NI Availto Com Stockholders
-429.64
-240.35%
-126.23
-31.63%
-95.90
-438.68%
28.32
Earnings From Equity Interest
—
0.00
0.00
-100.00%
0.86
Preferred Stock Dividends
179.00
—
—
—
Line Item Trend 2023-12-31
Total Assets
151.04
Current Assets
68.75
Cash Cash Equivalents And Short Term Investments
62.85
Cash And Cash Equivalents
7.58
Other Short Term Investments
55.28
Receivables
1.57
Accounts Receivable
0.90
Gross Accounts Receivable
1.09
Allowance For Doubtful Accounts Receivable
-0.18
Other Receivables
0.67
Inventory
—
Raw Materials
—
Work In Process
—
Finished Goods
—
Prepaid Assets
—
Restricted Cash
0.00
Assets Held For Sale Current
—
Other Current Assets
4.33
Total Non Current Assets
82.29
Net PPE
14.13
Gross PPE
38.41
Accumulated Depreciation
-24.28
Properties
0.00
Land And Improvements
0.16
Buildings And Improvements
2.63
Machinery Furniture Equipment
3.99
Construction In Progress
1.58
Other Properties
25.67
Leases
4.38
Goodwill And Other Intangible Assets
67.31
Goodwill
26.61
Other Intangible Assets
40.70
Investments And Advances
—
Other Non Current Assets
0.85
Total Liabilities Net Minority Interest
32.55
Current Liabilities
22.98
Payables And Accrued Expenses
13.02
Payables
1.73
Accounts Payable
1.73
Current Accrued Expenses
11.30
Pensionand Other Post Retirement Benefit Plans Current
8.25
Current Debt And Capital Lease Obligation
1.20
Current Debt
—
Other Current Borrowings
—
Current Capital Lease Obligation
1.20
Current Deferred Liabilities
0.51
Current Deferred Revenue
0.51
Other Current Liabilities
—
Total Non Current Liabilities Net Minority Interest
9.56
Liabilities Heldfor Sale Non Current
—
Long Term Debt And Capital Lease Obligation
5.89
Long Term Debt
—
Long Term Capital Lease Obligation
5.89
Non Current Deferred Liabilities
3.67
Non Current Deferred Revenue
1.82
Non Current Deferred Taxes Liabilities
1.85
Other Non Current Liabilities
—
Preferred Securities Outside Stock Equity
0.00
Stockholders Equity
118.50
Common Stock Equity
118.50
Capital Stock
0.00
Common Stock
0.00
Share Issued
256.40
Ordinary Shares Number
248.92
Treasury Shares Number
7.48
Additional Paid In Capital
2,084.92
Retained Earnings
-1,964.47
Gains Losses Not Affecting Retained Earnings
-1.95
Other Equity Adjustments
-1.95
Total Equity Gross Minority Interest
118.50
Total Capitalization
118.50
Working Capital
45.77
Invested Capital
118.50
Total Debt
7.10
Net Debt
—
Capital Lease Obligations
7.10
Net Tangible Assets
51.19
Tangible Book Value
51.19
Available For Sale Securities
—
Derivative Product Liabilities
0.00
Duefrom Related Parties Current
—
Dueto Related Parties Current
—
Investmentin Financial Assets
—
Notes Receivable
—
Other Inventories
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-87.83
-28.84%
-68.17
-1.86%
-66.93
-2.90%
-65.05
Cash Flow From Continuing Operating Activities
-87.83
-28.84%
-68.17
-1.86%
-66.93
-2.90%
-65.05
Net Income From Continuing Operations
-250.64
-98.55%
-126.23
-31.63%
-95.90
-438.68%
28.32
Depreciation Amortization Depletion
3.20
-29.32%
4.53
-32.12%
6.67
-38.06%
10.77
Depreciation
1.93
+31.29%
1.47
-19.40%
1.82
—
Amortization Cash Flow
1.27
-58.39%
3.06
-36.90%
4.85
—
Depreciation And Amortization
3.20
-29.32%
4.53
-32.12%
6.67
-38.06%
10.77
Amortization Of Intangibles
1.27
-58.39%
3.06
-36.90%
4.85
—
Other Non Cash Items
0.15
+114.36%
-1.02
+92.22%
-13.07
+83.66%
-79.98
Stock Based Compensation
10.87
+14.73%
9.47
-4.22%
9.89
-3.12%
10.21
Provisionand Write Offof Assets
—
0.00
0.00
-100.00%
0.94
Asset Impairment Charge
3.91
-90.31%
40.32
+272.16%
10.84
+867.41%
1.12
Deferred Tax
0.00
+100.00%
-1.79
-274.74%
-0.48
-219.33%
-0.15
Deferred Income Tax
0.00
+100.00%
-1.79
-274.74%
-0.48
-219.33%
-0.15
Operating Gains Losses
139.54
+4690.15%
2.91
+2306.82%
-0.13
+90.58%
-1.40
Gain Loss On Investment Securities
139.52
—
—
—
Unrealized Gain Loss On Investment Securities
—
—
—
0.00
Net Foreign Currency Exchange Gain Loss
0.00
-100.00%
2.92
0.00
0.00
Change In Working Capital
7.36
+62.75%
4.52
-73.50%
17.07
+147.82%
-35.70
Change In Receivables
-3.20
-872.71%
0.41
-96.61%
12.23
+190.50%
-13.51
Changes In Account Receivables
-2.99
-12358.33%
-0.02
-131.58%
0.08
+103.49%
-2.17
Change In Inventory
-9.21
0.00
0.00
-100.00%
2.34
Change In Prepaid Assets
-0.09
-109.48%
0.98
+31.15%
0.75
-71.56%
2.63
Change In Payables And Accrued Expense
15.64
+5724.82%
-0.28
+83.04%
-1.64
-44.02%
-1.14
Change In Accrued Expense
6.87
+475.97%
-1.83
-333.63%
0.78
+151.55%
-1.52
Change In Payable
8.77
+466.04%
1.55
+163.98%
-2.42
-738.79%
0.38
Change In Account Payable
8.77
+466.04%
1.55
+163.98%
-2.42
-738.79%
0.38
Change In Other Working Capital
4.66
+39.36%
3.34
-41.50%
5.71
+124.37%
-23.43
Change In Other Current Assets
-0.56
-563.33%
0.12
-6.98%
0.13
+227.72%
-0.10
Change In Other Current Liabilities
0.12
+327.27%
-0.06
+48.60%
-0.11
+25.69%
-0.14
Investing Cash Flow
-1.53
+92.59%
-20.71
-571.01%
-3.09
-101.36%
226.42
Cash Flow From Continuing Investing Activities
-1.53
+92.59%
-20.71
-571.01%
-3.09
-104.82%
64.11
Cash From Discontinued Investing Activities
—
0.00
0.00
-100.00%
162.31
Net PPE Purchase And Sale
-2.00
+76.76%
-8.58
-458.85%
-1.54
+68.81%
-4.92
Purchase Of PPE
-2.00
+76.76%
-8.58
-458.85%
-1.54
+68.81%
-4.92
Capital Expenditure
-2.00
+76.76%
-8.58
-458.85%
-1.54
+68.81%
-4.92
Net Investment Purchase And Sale
0.46
+103.77%
-12.19
-639.24%
-1.65
-102.41%
68.44
Purchase Of Investment
-208.01
-11.11%
-187.21
-1.18%
-185.03
0.00
Sale Of Investment
208.47
+19.11%
175.02
-4.56%
183.38
+167.93%
68.44
Net Business Purchase And Sale
—
—
—
—
Purchase Of Business
—
—
—
—
Net Other Investing Changes
—
0.06
-38.78%
0.10
-83.50%
0.59
Financing Cash Flow
90.05
-18.57%
110.58
+273.73%
29.59
+119.05%
-155.29
Cash Flow From Continuing Financing Activities
90.05
-18.57%
110.58
+273.73%
29.59
+119.05%
-155.29
Net Issuance Payments Of Debt
92.82
0.00
+100.00%
-43.22
+72.17%
-155.29
Issuance Of Debt
92.82
0.00
0.00
0.00
Repayment Of Debt
0.00
0.00
+100.00%
-43.22
+72.17%
-155.29
Long Term Debt Issuance
92.82
0.00
0.00
—
Long Term Debt Payments
0.00
0.00
+100.00%
-43.22
+72.17%
-155.29
Net Long Term Debt Issuance
92.82
0.00
+100.00%
-43.22
+72.17%
-155.29
Short Term Debt Issuance
—
—
—
0.00
Short Term Debt Payments
—
—
—
0.00
Net Short Term Debt Issuance
—
—
—
0.00
Net Common Stock Issuance
-1.66
-105.31%
31.24
-57.10%
72.81
0.00
Common Stock Payments
-1.66
0.00
0.00
—
Repurchase Of Capital Stock
-2.20
0.00
0.00
—
Proceeds From Stock Option Exercised
1.20
+247.40%
0.35
0.00
-100.00%
0.00
Net Other Financing Charges
-1.78
—
—
-0.59
Changes In Cash
0.68
-96.86%
21.70
+153.67%
-40.43
-764.93%
6.08
Effect Of Exchange Rate Changes
0.04
+229.63%
-0.03
+91.56%
-0.32
+61.31%
-0.83
Beginning Cash Position
29.52
+276.11%
7.85
-83.85%
48.60
+12.12%
43.34
End Cash Position
30.23
+2.43%
29.52
+276.11%
7.85
-83.85%
48.60
Free Cash Flow
-89.83
-17.03%
-76.76
-12.11%
-68.47
+2.15%
-69.97
Interest Paid Supplemental Data
3.51
+50042.86%
0.01
-99.40%
1.17
-86.28%
8.54
Income Tax Paid Supplemental Data
0.00
-25.00%
0.00
-80.95%
0.02
0.00
Amortization Of Securities
-2.21
-149.72%
-0.88
+51.19%
-1.81
-317.43%
0.83
Common Stock Issuance
—
31.24
-57.10%
72.81
0.00
Earnings Losses From Equity Investments
—
0.00
0.00
+100.00%
-0.86
Issuance Of Capital Stock
—
110.24
+51.41%
72.81
0.00
Net Preferred Stock Issuance
-0.54
-100.68%
79.00
0.00
0.00
Preferred Stock Issuance
—
79.00
0.00
0.00
Preferred Stock Payments
-0.54
—
—
—
Sale Of Business
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category